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REVIEW ARTICLE
What went wrong? The flawed concept of cerebrospinal venous
insufficiency
Jose´ M Valdueza1, Florian Doepp2, Stephan J Schreiber2, Bob W van Oosten3, Klaus Schmierer4, Friedemann Paul5,6 and Mike P Wattjes7
In 2006, Zamboni reintroduced the concept that chronic impaired venous outflow of the central nervous system is associated with
multiple sclerosis (MS), coining the term of chronic cerebrospinal venous insufficiency (‘CCSVI’). The diagnosis of ‘CCSVI’ is based on
sonographic criteria, which he found exclusively fulfilled in MS. The concept proposes that chronic venous outflow failure is
associated with venous reflux and congestion and leads to iron deposition, thereby inducing neuroinflammation and degeneration.
The revival of this concept has generated major interest in media and patient groups, mainly driven by the hope that endovascular
treatment of ‘CCSVI’ could alleviate MS. Many investigators tried to replicate Zamboni’s results with duplex sonography, magnetic
resonance imaging, and catheter angiography. The data obtained here do generally not support the ‘CCSVI’ concept. Moreover,
there are no methodologically adequate studies to prove or disprove beneficial effects of endovascular treatment in MS. This review
not only gives a comprehensive overview of the methodological flaws and pathophysiologic implausibility of the ‘CCSVI’ concept,
but also summarizes the multimodality diagnostic validation studies and open-label trials of endovascular treatment. In our view,
there is currently no basis to diagnose or treat ‘CCSVI’ in the care of MS patients, outside of the setting of scientific research.
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INTRODUCTION
In 2006, the vascular surgeon Paolo Zamboni1 reintroduced the
pathophysiologic concept of venous outflow pathology ultimately
leading to multiple sclerosis (MS). He based this concept
(or ‘the big idea’) on the well-known histopathologic features
of a perivenous localization of inflammatory MS lesions. He coined
the term ‘chronic cerebrospinal venous insufficiency’ (CCSVI) in
analogy to perivenous inflammation in chronic venous insuffi-
ciency of the legs. While Zamboni’s approach does not challenge
the commonly accepted understanding of MS immunopathology,2
it does relegate it to the final stage in the disease cascade.
According to the ‘CCSVI’ concept, MS pathology starts with
intracranial venous stasis based on a proximal obstruction of the
main cervical and thoracic veins. This leads to perivenous
diapedesis of erythrocytes in the white matter with subsequent
release of iron, the actual catalyst of the widely known and
accepted immune cascade.1 The theory of venous outflow
changes reaches back to the times of Charcot, who in 1868
provided an early histopathologic description of perivenous
inflammation in MS.3 In 1947, Putnam believing that thrombosis
of the cerebral veins was a common finding in MS patients
published preliminary results of treatment using dicoumarin in
MS patients after experiments using induced sinus thrombosis
in primates.4 However, his findings have not been validated or
revisited since this time. In 1986, Schelling posed the hypothesis
that venous intracranial or intraspinal reflux has a significant role
in the development of MS.5 Subsequently, Zamboni et al6–8
published several studies that were meant to support the ‘CCSVI’
hypothesis. They applied catheter angiographies to show various
extracranial venous outflow obstructions in the internal jugular
veins (IJVs) or azygos veins,9 and reported a correlation of the
clinical course of MS with specific patterns of venous
obstructions.10 Subsequently, they reported improvement in the
Multiple Sclerosis Functional Composite (MSFC) in relapsing
remitting (RR) MS and a reduction in Gadolinium enhancing
lesions on brain MRI during a mean follow-up of 18 months
in a small monocentric open angioplastic intervention study.9 The
‘CCSVI’ and its presumed efficacious therapeutic approach termed
as ‘liberation treatment’ caused enormous interest in the scientific
community, among patient support groups and in the media.
Several clinical trials on angioplasty have started since, and
numerous desperate MS patients seek relief from their incurable
disease through questionable medical procedures. However, in
the meantime the number of publications that refute the ‘CCSVI’
hypothesis has far exceeded that of its supporters. This review
aims to analyze and critically comment on methodical aspects of
‘CCSVI’ in the context of (patho-)physiologic plausibility, which
refers mainly to color-coded duplex ultrasonography (US), which is
the only method according to Zamboni to define ‘CCSVI’.
In addition, we aim to comprehensively present the literature on
studies reproducing and confuting this theory, including
treatment studies.
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ULTRASOUND STUDIES
Venous Drainage and Neurologic Diseases
Currently, US is one popular technique for imaging the venous
system. In the field of neurology, research begun to focus in the
midnineties of the past century primarily on impaired venous
drainage in primarily venous disorders like cerebral venous and
sinus thrombosis.11,12 Subsequently, primarily nonvenous disease
entities were studied. In transient global amnesia, an increased
prevalence of IJV valve insufficiency (IJVVI) was seen which
occurs in 20% to 30% of the normal population, but in up to
70% of transient global amnesia patients.13–15 A significantly
increased prevalence of IJVVI was recently also shown for transient
monocular blindness,16 leucoaraiosis,17 primary exertional head-
ache,18 primary intracranial hypertension,19 and chronic obstruc-
tive pulmonary disease.20 More recent research data suggest that
the venous system may have a considerable role in arterial stroke.
Yu et al21 found that an impaired ipsilateral venous drainage due
to a hypoplastic or aplastic lateral sinus (transversus and sigmoid
sinus) was accompanied by pronounced infarction leading to
higher morbidity and mortality. A further study analyzed whether
collapsed veins as a result of intracranial artery occlusion might
influence the extent of damaged brain tissue.22
‘Chronic Cerebrospinal Venous Insufficiency’ Criteria—Are They
Sound?
In 2007, Zamboni published the first US study investigating the
relationship between impaired drainage and MS. The study was
limited to the intracranial circulation, and provided the first
description of an intracranial venous reflux in the deep cerebral
veins (DCVs) defined by a retrograde flow of at least 0.5 second.6
Two years later, he published a combined extracranial and
intracranial US study, postulating four other criteria indicating
impaired venous drainage, above the intracranial venous reflux
which would later become his second ‘CCSVI’ criterion.7 He
specified the first criterion as extracranial reflux (40.88 second) in
the IJVs and/or vertebral veins (VVs) in sitting and lying position;
the third criterion as a stenosis defined by a reduction in the
crosssectional surface area (CSA) of the IJV of X50% or beyond a
set threshold of 0.3 cm2;8 the fourth criterion as a lack of flow in
the IJV and VV again in supine and/or sitting posture despite
visible vascular lumens; the final criterion as reverted postural
control, in which the IJV does not collapse as would be
physiologically expected in upright position. The study in which
these criteria were presented and applied examined 109 patients
and 177 nonaffected people. Zamboni found that each MS patient
met at least two criteria, while none of the control group did. Thus,
the sensitivity, specificity, the predictive, and negative-predictive
values were each 100%. These astonishing results prompted other
groups to attempt to confirm the findings using color-coded
duplex sonography. Some research groups also found a very high
prevalence of at least two positive criteria for MS patients alone,23
while others described a relatively high proportion of healthy
controls24,25 and patients with other neurologic diseases fulfilling
the criteria.26 In contrast, several other groups found that
no or only few MS patients and healthy controls fulfilled the
‘CCSVI’ criteria.27–33 Despite these contradictory results, balloon
angioplasty and stenting treatments of the venous system were
performed based on these findings and are currently performed
around the world.34
The experience in ultrasonographic examination of cerebral-
venous hemodynamics is limited, despite the fact that the
technique is quite simple, and consequently well-researched and
validated results describing normal and impaired venous drainage
are lacking. Substantial data describing the normal venous blood
flow using US have been published by our Berlin Charite´ research
group in the past 15 years. Zamboni et al7–9 refer to our studies
describing the venous outflow findings in MS patients and healthy
controls. However, from our point of view, they misinterpreted our
data leading to the logical conclusion that the Zamboni criteria
are based in part on a misconception of our work. For this reason,
we consider a methodological critique of ‘CCSVI’ concept a
priority. We also consider the rash establishment of ‘CCSVI’ and
particularly the concept of a ‘CCSVI’ syndrome35 in the scientific
literature, as questionable, because of the lack of scientific
validation.
Recently, Laupacis et al36 presented the first meta-analysis of
existing results on the ‘CCSVI’ hypothesis, including all studies
with MS patients and controls published so far. The meta-analysis
explicitly addressed the question of ultrasound examination
quality and suggests that one possible reason for a low
prevalence of ‘CCSVI’ in some studies might be the insufficient
experience of the investigators.36 Interestingly, their analysis
shows a significant negative association between the postulated
qualification/experience of certain research groups and the
number of their published ultrasound studies in this field.
The US examination of veins responsible of the intracranial
drainage requires the consideration of the particular features and
specific characteristics of the cerebral and cervical venous system
which is essential for correct differentiation between physiologic
variants/anomalies and pathologic findings. For example, unlike to
other parts of the body, the cerebral venous system is valveless
allowing a reversal of blood flow direction.37,38 Furthermore,
intracranial veins are not capacitance vessels like the veins of the
extremities, as they only dilate to a limited degree. A further
characteristic is that they do not collapse in a vertical body
position, because the skull is a sealed cavity.39,40 The situation is
similar in the spinal cavity so that the term ‘craniovertebral cavity’
might be more accurate than the commonly referred to sealed
‘intracranial cavity’. Another unique feature of cerebral venous
drainage is its dependence on posture. Whereas in supine position
the IJVs are the main drainage pathways, in upright position
the IJVs generally collapse with the VVs and intraspinal
veins compensating to a large extent.41–44 However, the IJVs are
not always the main drainage veins in the supine position. In
B30% of healthy subjects, the extrajugular drainage pathways are
at least similarly important for cerebral venous drainage.45 Finally,
anatomic and angiographic studies have shown that the drainage
of the cerebral blood is asymmetric with a preferential outflow via
the IJVs of the right side.46,47 These special characteristics are
indispensable in the understanding of the craniovertebral venous
drainage, although many of its aspects, for example, the postural
mechanisms of the venous outflow have to be elucidated.
Point-by-Point Methodological Critique of the Zamboni Criteria
(1) Intracranial reflux. Zamboni introduced the criterion of
intracranial reflux in 2007 and has not changed it afterwards. He
defines intracranial reflux as a retrograde flow within the inner
venous system of 40.5 second.6 In this study, referring to
intracranial veins, for which normal flow velocities and detection
rates had been published in the past, is written in the Methods
section: ‘using the trans-temporal acoustic bone window, we
insonated at least one of the deep middle cerebral veins (dMCVs),
including basal veins of Rosenthal, great vein of Galen, and internal
cerebral veins, according to criteria previously described [Valdueza
et al, 1996; Stolz et al, 1999; Zipper et al 2002]’.48–50 However, none
of these veins are presented in the figures. Instead, he shows that
color-coded duplex signals of undefined vessels located in the
white matter around the third ventricle, which are simply
designated as orthograde and thus normal if blue-coded and as
retrograde and thus pathologic if red-coded. The terminology
used in the study is ambiguous. For instance, Zamboni refers to a
group of veins as the ‘deep middle cerebral veins’, but presumably
means the ‘deep cerebral veins’. The deep middle cerebral vein is
a clearly distinguishable vein that runs parallel to the middle
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cerebral artery and generally flows into the basal vein of Rosenthal
(BVR).51 In 2009, they again published a misleading image of an
intracranial vein.7 While the internal venous system, comprising
the deep middle cerebral vein, the BVR, the internal cerebral vein,
the vein of Galen, and straight sinus, is now correctly designated
as the DCVs, Figure 2 of the paper presents a vein in the
subcortical gray matter without any further identifying details.
As the vein in the figure is coded red, Zamboni diagnoses venous
reflux. A corresponding figure of a physiologic finding, which
should in this case be coded blue, is not shown, although it is
referred to in the figure legend. Another point of criticism is that a
Doppler spectrum of a venous vessel is not shown although
the Methods section states that the flow spectra and velocities in
the DCVs were measured. The Doppler spectrum is important for a
reliable differentiation from arterial signals based on its pulsatility,
which is generally clearly lower for veins. Besides that, the typically
low venous blood flow velocity often requires the use of a Doppler
spectrum for a correct analysis of venous flow direction. Thus,
venous anatomy and hemodynamic cannot be assessed just
by color signals. Furthermore, arteries can overlap with veins in
imaging, which is another reason that the Doppler spectrum
should be derived for every vascular segment examined.
Zamboni defines venous reflux of DCVs as a red color-coded
signal or rather as a flow signal toward the probe. This seems to be
very crucial. Although the DCVs and the straight sinus run toward
the occiput, causing predominantly a blue color-coded signal
away from the probe, the BVR, for example, shows a red signal
running toward the probe along its proximal section. A flow away
from the probe is seen in its middle and distal sections.
Correspondingly, the posterior cerebral artery, which runs parallel
to the BVR, shows a red signal proximally and a blue signal distally
(Figure 1). Due to its anatomic position in relation to the midbrain
and the posterior cerebral artery, the BVR is detectable in almost
100% using color-coded duplex US, particularly in its middle and
distal sections. In comparison, the other DCVs are more difficult to
investigate using transcranial color-coded sonography. This
especially applies to the internal cerebral veins, showing a
detection rate of B10% to 20%.48,52 As the anatomy of the BVR
is extremely stable and forms part of the internal venous system, a
flow toward the probe in the distal BVR can definitely be regarded
as a pathologic finding. However, an image of a retrograde flow in
the BVR was never shown by Zamboni. As a side note, a
retrograde flow signal in the BVR can also be present in cerebral
venous thrombosis12,48 and tumor-induced obstructions of the
straight sinus,53,54 as well as in arterio-venous angioma.55
Another crucial question regards Zamboni’s definition of
intracranial reflux as a retrograde flow of longer than 0.5 second.
This threshold derives from studies on venous insufficiency of
the legs, in which a reflux of at least 0.5 second after deflating a
compression cuff was defined as pathologic.56 Although we do
agree that a spontaneous or induced retrograde flow of half a
second in the deep venous system is probably not physiologic, a
direct transfer from legs onto a different anatomic environment,
namely intracranial drainage remains problematic.
Figure 1. Transcranial color-coded duplex sonography of the basal vein of Rosenthal (BVR) with low flow velocity and pulsatility together with
the posterior cerebral artery (PCA) with high flow velocity and pulsatility using a transtemporal axial approach at the mesencephalic plane.
Notice the physiologic change of blood flow direction with a red-coded flow toward the probe (top) in the proximal and blue-coded away
from the probe (bottom) in the distal part of the BVR as well as in the PCA.
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(2) Extracranial reflux in the internal jugular vein and the vertebral
vein. In the 2009 study, Zamboni et al7 defined a retrograde flow
in the IJV or VV as lasting 40.88 second. The Methods section
states that ‘For each assessment the direction of flow is [analyzed
either with the pulsed wave mode and the sample placed in the
vessel, at a 601 angle, or with the color-coded mode, by comparing
the color of the flow in the IJV/VV with that of the satellite carotid
and/or vertebral artery, respectively. Either the IJVs or the VVs can be
examined by using both the transversal and/or the longitudinal
cervical access’. Again, from the methodological point of view, we
strongly recommend assessment by pulsed-wave Doppler mode
in addition to color-coded mode. The longitudinal oriented
cervical veins have to be examined by ultrasound in longitudinal
planes in each case, as due to the Doppler formula, reliable
measurements are dependent on the ultrasound angle, and
ultrasound application at 901 can misleadingly suggest zero flow.
The presented figure in this paper only shows a transversal section
through the IJV and the common carotid artery, which both show
a red signal, thereby suggesting a retrograde flow in the IJV.
Transversal IJV examination may be adequate for determining
flow direction in hurried routine examinations especially as using
this method the probe can be adjusted to improve the angle of
the ultrasound beam. In clinical research, stringent
methodological standards have to be fulfilled, and the cervical
veins definitely have to be assessed to determine the longitudinal
flow direction.
Additionally, the IJV can also exhibit a nonpathologic oscillating
signal with a positive and negative flow that is often observed,
especially in the elderly. This is instantly identifiable in the
longitudinal and transverse imaging analyzing the Doppler
spectrum in the pulsed wave mode, but which can suggest
reflux using only a snap shot with the color-coded US (Figure 2).
Zamboni et al35 define extracranial reflux as having a duration
of 40.88 second, in contrast to intracranial reflux, which is
assigned a duration of 40.5 second. The different threshold for
intracranial and extracranial reflux remains unanswered. They
argue that the value of 40.88 second allows to differentiate
between a physiologic and pathologic reflux, adopting this
threshold value from a study that examined IJVVI during a
Valsalva maneuver (VM).57 The validity of this approach is
questionable, because reference values gained during a VM do
likely not apply to situations where flow measurements take place
in resting conditions. The reference to the VM is relevant to the
extent that to date only the presence of IJVVI has been evaluated
as criterion of compromised venous drainage. Apart from the
0.88 second proposed by the research group of Nedelmann as
reflux threshold, other methods have been proposed to define
IJVVI.20,58,59 An increased prevalence of IJVVI has been found for
several neurologic (transient global amnesia, amaurosis fugax,
and leucoaraiosis)13–17 and non neurologic diseases (primary
pulmonary hypertension, chronic obstructive pulmonary disease,
and primary exertional headache).18,20 The sole publication on MS
patients reported no significant difference to the control group.31
Despite the fact that neurologists debate the significance of valve
insufficiency for several years, the Zamboni group has not yet
addressed this in MS patients, not even in the form of a critical
discussion of the literature available to date.
Second, it seems inconsistent to define pathologic reflux in the
intracranial and extracranial veins by two different time values.
Despite these methodical problems, similarly to the intracranial
system, a retrograde flow in the IJV or VV during resting conditions
should be interpreted as a sign of a compromised venous system.
Pathologic retrograde IJV flow has been described for innominate
vein occlusion.60 However, this does not necessarily have a clinical
consequence, as the literature also includes a description of a
postural retrograde IJV flow in response to compression of the left
brachiocephalic vein in the supine position.61 We recently
observed such a case, in which the ipsilateral VV exhibited a
Figure 2. Extracranial color-coded duplex sonography of the internal jugular vein (IJV) and common carotid artery (CCA) in a transverse (top)
and longitudinal (bottom) plane. Blood flow direction in the IJV seems to vary at different time points using a transverse insonation (top left:
orthograde flow, blue coded; top right: retrograde flow, red-coded). Additional insonation in the longitudinal plane shows the continuous
orthograd flow, blue-coded.
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retrograde flow in the supine position, turning in an orthograd
flow in the upright position (Figure 3).
(3) Proximal stenosis of the internal jugular veins. Zamboni
introduced two different criteria of proximal IJV stenosis in 2009.
An at least 50% reduction in the vascular CSA of the IJV was his
first suggestion.7 Shortly after, he considered a threshold of
0.3 cm2 of the CSA of the IJV as a stenosis.8 Both criteria can be
refuted based on methodological and anatomic considerations.
The IJV is significantly wider at its point of origin in the upper bulb
and its confluence into the subclavian vein in the lower bulb.62
The crosssection of the medium section, which unlike the cranial
sections can always be imaged using duplex sonography, varies
greatly depending on the position of the head, posture, and the
central venous pressure. Defining stenosis as a 50% reduction in
the vein’s CSA is therefore not practical. Additionally, the location
of the designated normal reference lumen has never been
defined.
The second approach seemed more plausible, as it claimed to
be based on a published US study by Lichtenstein et al,63 in which
an IJV crosssection of p0.3 cm2 apparently ‘was not found in any
examined subject’. However, the study in fact stated that 23% of
the subjects had an IJV area of p0.4 cm2 and the included
diagram shows 21 measurements with a CSA ofp0.3 cm2 without
pathologic meaning. Furthermore, interpretation was already
limited as the study focused on patients in intensive care and
did not include healthy subjects. Therefore, Zamboni et al based
their conclusions on misinterpretation of a previous study. It has
also to be mentioned that in this work the area of the IJV was
measured 15mm above the cricoid cartilage which does not
exclude smaller areas at more proximal or distal locations.
Moreover, one other ultrasound study performed in 10 healthy
volunteers measuring CSA of the IJV just above the carotid
bifurcation showed a range of CSA on the right IJV between 0.11
and 0.77 cm2 and on the left IJV between 0.13 and 0.5 cm2 again
refusing the proposal of the Zamboni group.64 This is not
surprising, as central venous drainage is not only dependent on
posture, but as mentioned above, shows a preference for the right
side.46,47,63 This has a physiologic basis, in that the blood of both
hemispheres primarily flows via the unpaired superior sagittalis
sinus into one transverse sinus, preferentially the right, and finally
enters the ipsilateral IJV. In contrast, the unpaired straight sinus
collects the blood of the centrally located DCVs (temporomesial,
basal ganglia, and thalamus) and flows preferable into the left IJV
primarily via the left transverse sinus. The real flow conditions and
vascular diameter of the IJVs at least depend on the anatomic
configuration of the confluens sinuum. In the simplest case seen in
an autopsy study on 600 adult cadavers, in B25% of cases the
confluens sinuum forms a complete connection between the
superior sagittal sinus and straight sinus with a similar distribution
of venous blood to both IJVs. However, in B10% of cases the
confluens sinuum is missing, such that hemispheres drain
completely separately.65 Venous drainage is dominated by the
right side in B50% of cases and is dominated by the left side
or is distributed evenly across both sides in B25% of cases.
Consequently, particularly in the left IJV, a low blood flow volume
with small vessel diameter should be considered as physiologic,
rather than pathologic.
(4) Absence of blood flow in otherwise detectable internal jugular or
vertebral veins in lying and/or upright posture. The question
arising here is whether this criterion reflects a pathologic
condition. The fact that normal cerebral venous drainage is
strongly dependent on posture was already mentioned above.
Whereas the IJVs dominate in most subjects in the lying position,
the extrajugular drainage pathway, including the VVs, has an
important role in the upright position, while the IJV collapses to
various degrees. In this posture-dependent interplay between the
IJVs and the extrajugular veins, it is physiologically comprehen-
sible that one of them may display no flow even if lumens are
visible. In a first study, we examined 23 young healthy subjects
with duplex sonography in different body positions.44 While in the
supine position at 01, venous blood outflow was found in at least
one IJV in all subjects. In the upright position, nine subjects
showed complete cessation of blood flow in both IJVs. In two
subjects, flow already ceased at 151 with visible lumens. Thus, 39%
of the subjects showed bilateral zero flow in the IJVs in at least one
posture. A concomitant flow increase was found in the VVs, not
compensating the complete difference of blood flow in the IJVs.
An absent flow in the IJV even in the supine position has been
described in a further investigation of our group.45 The postural
dependency of cerebro-venous outflow has also been shown in
MRI investigations41 and was already observed using a
conventional catheter approach.66,67
Zamboni et al35 used these results to support their arguments,
but substantially misrepresented these findings: ‘We assessed the
lack of a Doppler detectable venous flow in the IJVs and/or VVs
despite numerous deep inspirations. In normal subjects, this finding
was never observed with the head in any position [Valdueza et al
2000]y’ It is crucial to clarify that a cessation of blood flow in one
or both IJVs in supine or upright position cannot be considered to
be clinically relevant.
The VVs also warrant particular attention. In early anatomic
studies, the VV was not considered to be a relevant vessel, but
instead as a venous plexus around the vertebral artery. In contrast
to the IJVs, which have been the focus of anatomic and
physiologic research since the first days of duplex
sonography,68,69 up to now only one paper has been published
reporting detection rates and flow velocities of 138 healthy
subjects (mean age±s.d. 42.1±14.5 years) in supine position.70
Figure 3. Postural changes of blood flow direction in the vertebral
vein (VV) and internal jugular vein (IJV) in a healthy subject.
Retrograde blood flow in the VV (top) and IJV (central) in supine
position turning into an orthograd flow in both vessels after
postural change toward the sitting position (bottom) (VV not
shown). Note the orthograd flow in the vertebral artery (VA) and
common carotid artery (CCA).
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A bilateral flow was seen in 62% of the subjects, while 17%
showed unilateral flow. Twenty-one percent showed no flow
bilaterally, although the VV lumens were generally visible proximal
to the vertebral artery. The prevalence of blood flow changes in
the VVs seems to be age related. In a younger population (mean
age±s.d. 27±7 years), only 4% presented no flow in the VVs.45
These results underline that the cerebral venous drainage is
strongly dependent on the postural status, in which the IJVs
usually assume the main role in supine position, whereas its
significance decreased as the posture becomes more upright due
to IJV collapse and blood flow in the VVs increases as partial
compensation. Thus, a lack of flow in the VV in supine posture in a
noncollapsed vessel is not pathologic. In contrast, a lack of a
compensatory flow increase in the VVs in upright position seems
to be unusual in our experience, and a lack of VV flow in standing
position when the lumens are visible would be practically
impossible.
As a side note, the criterion of zero flow in a visible vein has
been a key source of uncertainty for research groups that have
applied the Zamboni ultrasound protocol, as it was unclear
whether the definition referred to a lack of flow unilateral or
bilateral, in one or both postures or on both sides in both
postures. Our initial interpretation of his argument was that a lack
of flow had to present in both IJVs or both VVs in both positions.
This would explain why our application of this Zamboni criterion
found much lower prevalence than Zamboni himself. Only the
accidental discovery of a reference to our publication on the
internet brought to our attention that Zamboni considers zero
flow in a single vein, independently of posture, to be a pathologic
symptom.71
It should also be pointed out that ultrasound examinations of
the VVs often lead to an unintentional compression of the IJVs and
thus to a compensatory increase in the VV flow. We observed a
similar phenomenon in patients with a postoperative status after
neck dissection with resection of an IJV.72 It seems very likely to us
that groups unable to find a lack of flow in the VV fell victim to
false-positive results. Even experienced investigators might find
positive blood flow in the VVs due to accidental compression of
the IJVs when the subject changes posture. But, again, we must
emphasize that the absence of blood flow is not a pathologic
condition per se.
(5) Lack of collapse of the V. jugularis interna in upright posture.
Collapse of the IJVs in upright position is a physiologic effect of
the decrease in hydrostatic pressure and should not be considered
as a pathologic phenomenon. Therefore, lack of postural-
dependent IJV collapse may indicate proximal venous obstruction
and has been observed in a few cases in one of our own studies.30
However, in subsequent examinations we found that we had
probably mistaken other veins for the IJV in the upright position,
as the IJV was frequently completely collapsed. To identify the IJV
with certainty, researchers should either continue ultrasound
monitoring of the IJV as the subject stands or sits up or perform a
short VM to dilate the IJV. Furthermore, to assess the real
hemodynamic relevance in cases of absent venous postural
collapse the differences of blood flow volume between the supine
and sitting body position should be analyzed. In the only
one published work using blood flow volume measurements,
we found a significant higher decrease in blood volume flow in
the sitting position in normal subjects, suggesting an even better
venous drainage via the IJVs in this position in MS patients.30
What Remains of the Zamboni Criteria?
Both the number of criteria (5) and the idea that two positive
criteria suffice for the diagnosis of ‘CCSVI’ seem quite arbitrary.
There is some evidence that a retrograde flow in clearly defined
intracranial venous vessels of the deep system should be
considered as pathologic criterion. The same is true for reflux in
the extracranial veins of the neck, although in some cases the
effect could be due to a nonpathologic, posture-dependent
compression of the brachiocephalic vein. Of course, any applica-
tion of the reflux criteria should be based on definitions which are
actually not available. Both reflux criteria of Zamboni are
insufficient and methodologically inadequate. Research groups
with long-standing scientific expertise in ultrasonic vein analysis of
cerebral drainage, such as the group of Nedelmann/Mayer and our
own group, have not been able to show extracranial or intracranial
reflux in MS patients or healthy controls.30,31 This suggests that
the phenomenon does not exist in MS.
As outlined, the absence of blood flow and that what Zamboni
called stenosis are in fact physiologic and not pathologic. Their
inclusion in the criteria was based on misinterpretations of former
studies.
As at least two of the five criteria (proximal IJV stenosis and
absence of blood flow in the IJV(s) and/or VV(s)) are in fact a
nonpathologic phenomenon, it does not surprise that their
prevalence can surely be observed widespread. The proportion
of cases meeting at least two of the criteria would have been
higher also in our study, if we had interpreted Zamboni’s fourth
criterion in the above-mentioned manner.
Following the above explanations, the 2009 ‘CCSVI’ concept of
the Zamboni group is in fact not salvable. Very recently, Zamboni
published a so-called consensus manuscript, in which the early
‘CCSVI’ protocol for venous analysis was newly adapted.73
A detailed discussion of all alterations would be out of frame for
the current manuscript. Concerning the extracranial and intra-
cranial reflux the new criteria now also include a bidirectional flow
as a pathologic pattern. To our opinion, this phenomenon is rather
indicative for an IJVVI and should therefore also be a possible
finding in the healthy population. Considering the intracranial
veins, an unusual and so far nonvalidated insonation approach is
being introduced. The p0.3 cm2 ‘stenosis’ criterion is modified to
a mandatory missing CSA increase during a standard VM. They
added an additional alternative criterion including ‘and/or other
B-mode anomalies’, like intraluminal defects such as flaps, septa,
or malformed valves combined with hemodynamic changes
(block, reflux, and increased blood flow velocity). Furthermore,
the zero-flow criterion on one side in the IJVs and/or VVs in both
body positions permits now a bidirectional flow in one position
and a zero flow in the other position. Finally, while the early
criterion 5 required CSA increase in the sitting position, now a
position-independent CSA is sufficient as a pathologic criterion.
With the ‘old’ ‘CCSVI’ criteria being refuted, the ‘new’ criteria
seem to call for new confirmatory studies to confirm or refuse the
new results.73 However, the scientific quality appears unaltered
low, as the core statements of our critical discussion also apply to
the new modified criteria.
Venous obstruction in neurologic diseases is an exciting area
of research and misleading hypotheses should not be allowed to
compromise future investigations. Therefore, we are concerned
that Zamboni’s concept of ‘CCSVI’ will be adopted by himself or
other groups for investigations in other fields in neurology.
OTHER IMAGING STUDIES
Magnetic Resonance Venography
Substantial points of criticism of ultrasound methodology are
operator dependency and the limited options in terms of
operator blinding. Magnetic resonance venography (MRV) is a
well-established and robust method for the evaluation of the
intracranial and extracranial (neck) venous system in vivo.74–76
A first study using a 3D contrast-enhanced MRV and 2D phase-
contrast flow quantification in 21 patients with RR MS and 20
healthy controls subjects showed no substantial differences
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between MS patients and healthy controls in terms of blood flow
or a possible reflux in the IJV. A narrowing of the IJV was observed
in three patients who also showed a corresponding lower blood
flow in the IJV.77 Similar results were obtained in a second study
using 3D contrast-enhanced and 3D phase-contrast MRV in
combination with a 2D phase-contrast flow quantification of the
internal cerebral veins and straight sinus. Anomalies of the
extracranial (neck) and/or intracranial venous system could be
observed in 50% of the MS patients and 40% of the healthy
controls. An additional associated anomaly of the venous drainage
(e.g., compensatory collateral drainage) was found in six MS
patients and five healthy controls. Interestingly, none of the MS
patients and healthy controls (regardless whether they had a
venous anomaly or not) showed a venous backflow in the internal
cerebral veins or straight sinus.78 These findings underscore once
again the assumption that the venous anomalies in terms stenosis
are not pathophysiologically relevant and rather reflect anatomic
variants than pathologic conditions.78,79 Magnetic resonance
venography seems also more sensitive to detect IJV narrowing
compared with color-coded duplex US.80
Even in terms of IJV morphology and the presence of a
prominent/collateral extracranial venous drainage, no significant
differences between MS patients and control subjects could be
detected in a study including 57 MS patients and 21 controls.81 In
this context, it is worth noting that venous anomalies (narrowing)
can more frequently be found in older MS patients with a longer
disease duration, suggesting that these findings may be age
related.82
A substantial criticism regarding the assessment of the
venous systems with MRV is the limited value of conventional
MRV compared with US in the detection of venous pathology
particularly in terms of specificity.83 The IJV narrowing or occlusion
assessed by MRV in supine position does not need to be
considered as pathologic at all since these findings are not
reproducible in the upright position using positional MRV.84 In
addition, advanced MRI techniques such as phase-contrast flow
studies and magnetic resonance perfusion are well suited to
investigate whether venous outflow changes in terms of ‘CCSVI’
do have any impact on intracranial venous blood flow. As
mentioned above, a combined MRV and phase-contrast flow
study did not show any intracranial reflux in MS patients and
healthy controls with or without venous abnormalities on MRV.79
Another study found flow changes in MS patients with and
without venous narrowing in the extracranial venous systems.85
However, it remains questionable whether these changes are
relevant since the intracranial part has to be considered as the
crucial part in terms of venous backflow and pressure.
Recent studies using high-field MRI and susceptibility-weighted
imaging have nicely shown the perivascular inflammation pattern
in MS by sensitively visualizing the small venous vessels in the
periventricular and deep white matter.86 It has been conclusively
showed that MS patients show a reduced visibility of cerebral
veins. This finding seems to be inversely correlated with the
periventricular and whole-brain T2-lesion load suggestive of
chronic inflammatory changes including gliosis and fibrinoid
deposition.87,88 One single study found a link between the
decreased visibility of venous vessels and venous outflow
changes suggestive of CCSVI.89 However, based on the CCSVI
theory, we would expect the opposite since venous obstruction
would rather lead to an increased diameter and visibility of
cerebral veins. The findings on cerebral veins are also reflected by
low magnetic resonance perfusion measures (cerebral venous
blood flow and cerebral venous blood volume) and other
measures suggesting an underutilization of oxygen in MS brain
tissue.90,91 Magnetic resonance perfusion examinations (dynamic
susceptibility contrast-enhanced) in MS patients and control
subjects with or without fulfilling ‘CCSVI’ criteria did not show
any substantial relationship between MS and ‘CCSVI’ in terms of
cerebral perfusion parameters. Moreover, no relationship between
perfusion parameters in ‘CCSVI’ subjects and clinical outcome
measures could be observed.90 This once again underscores the
implausibility of the ‘CCSVI’ concept in terms of pathophysiology.
Selective Venography
There is currently limited data on selective catheter venography
addressing the issue of venous abnormalities/anomalies in MS
patients. In accordance to the above-mentioned MRV study, a
study using selective venography on 42 MS patients with different
disease courses and disease duration showed that the occurrence
of venous anomalies might be depending on the age and disease
duration. A low prevalence was observed in early disease courses
such as clinically isolated syndrome and early RR-MS (24%). Only
one of the included clinically isolated syndrome patients showed
an extracranial venous stenosis. In contrast, the prevalence
increases substantially in patients with longer disease durations
of 410 years (92%).92
TREATMENT STUDIES
Notwithstanding the questionable scientific basis, many patients
with MS decide not to wait until the scientific dispute has come to
an end and have percutaneous transluminal angioplasty (PTA;
‘liberation treatment’) performed. Some of them report the results
of their treatment in social media, sometimes in structured
databases (e.g., http://www.ccsvi-tracking.com). Even respected
MS clinics have opened a registry, which obviously will never
answer the question whether the treatment is effective or not
(e.g., British Columbia CCSVI Registry).
There is still discussion whether the current state of knowledge
justifies the allocation of money and other resources to trials of
PTA in patients with MS and whether those trials are ethical.93,94
Nevertheless, some institutes are planning trials and others
are already recruiting patients (http://clinicaltrials.gov/ct2/results?
term=ccsvi).
EFFICACY OF PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY
FOR MULTIPLE SCLEROSIS/‘CHRONIC CEREBROSPINAL
VENOUS INSUFFICIENCY’
So far, a few reports on open-label treatment results have been
published, the first in 2009. In this open-label study, patients with
RR (n¼ 35), secondary progressive (n¼ 20) and primary progres-
sive (n¼ 10) MS were treated with PTA.9 In RR patients, the
annualized relapse rate did not change after PTA (0.9 versus 0.7),
but the number of relapse-free patients (27% versus 50%),
gadolinium-enhancing MRI scans (50% versus 12%), and scales
of disability and quality of life (MSFC and Multiple Sclerosis Quality
of Life) improved. There is no mention of the results of MRI studies
in patients with progressive MS. It is not clear whether all 65
treated patients contribute to the 18-month follow-up (only
percentages of patients who reach a certain end point are given,
no absolute numbers). Quality of life scales improved in primary
progressive but not in secondary progressive patients, the MSFC
did not change in either group. In the RR group, 33 of 35 patients
were on immunomodulatory or immunosuppressive treatment,
with only limited data on treatment available.95
In a later publication, Zamboni et al35 try to address some of
the concerns mentioned above.96 This is a case control study of
15 patients with RR-MS followed for 12 months. Eight patients
received immediate PTA and seven patients with a delay of
6 months. All patients were on immunomodulatory medication.
Unblinded clinical data show one relapse in the immediate
treatment group and four in the delayed group. Whether the four
relapses in the delayed treatment group occurred before or after
treatment is not clear. No Expanded Disability Status Scale97
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changes were seen, but the MSFC had improved in both
treatment groups after 6 and 12 months. Regarding the blindly
assessed MRI data, the 8 patients in the immediate treatment
group accumulated 12 new T2 lesions (an average of 1.5 per
patient) compared with 5 new T2 lesions in the 6 remaining
patients (an average of 0.83 per patient; one dropout because of
‘familial reason’) in the delayed treatment group after 6 months;
after 12 months (end of study), the immediate treatment group
had accumulated 34 new T2 lesions (an average of 4.5 per patient)
compared with 12 new T2 lesions in the delayed treatment group
(an average of 2.0 per patient). The delayed treatment group
accumulated more new lesions in the 6 months after PTA than in
the six preceding PTA (7 versus 5). Although delayed treatment
patients accumulated fewer lesions, the authors report a far higher
median change in T2 lesion volume after 6 and 12 months in this
group compared with the immediate treatment group. This seems
to be a contradiction, but this is not discussed in the publication.
Striking reductions in T1 hypointense lesion volumes were seen in
all groups and are not discussed or explained. In the abstract, the
authors present data that appear to support their hypothesis,
leaving out data indicating the opposite. Data in the abstract can
be found in the main text, but differ from those provided in the
main table. There are calculation errors and inconsistencies
between text and tables.
Malagoni et al98 studied the effect of open-label PTA on
measures of fatigue in 31 patients with MS. Five patients did not
complete the study. They found statistically significant and
clinically relevant improvements on the Modified Fatigue Impact
Scale99 and the Fatigue Severity Scale100 after 1, 6, and 12 months,
with a tendency to decline in the year after treatment. In addition,
the 6-minute walking distance improved 1 month after treatment,
but the authors do not report the results after 6 and 12 months.
The authors concluded that PTA treatment was effective.
Kipshidze reports treatment of 4 MS patients with PTA, and
concludes that this treatment is effective, but does not provide
the underlying data.101
Kostecki presents 6 month follow-up data on 36 MS patients
treated by PTA.102 Quality of life scales such as the Multiple
Sclerosis Impact Scale (MSIS-29)103 improved temporarily at
month 3, whereas the Heat Intolerance scale and Fatigue
Severity Scale were still improved at the end of follow-up. The
Expanded Disability Status Scale did not respond to the treatment,
so that the authors concluded that the treatment ‘did not have an
influence on the patient’s neurologic condition; however, in the
midterm follow-up, an improvement in some quality-of-life
parameters was observed’.
A somewhat larger open-label study assessed the results of PTA
in 94 patients with MS after 6 months with MSIS-29, Fatigue
Severity Scale, and Epworth sleepiness scale104 questionnaires and
found improvements. No MRI studies were reported.105
In 2012, Salvi106 reported a 2-year open-label follow-up of
29 PTA-treated patients, 17 of whom were from the cohort of
65 patients originally reported by Zamboni.9 These patients were
seen every 3 months, both in the 2 years preceding PTA and in the
2 years after treatment. The mean exacerbation frequency in the
follow-up years was 0.45 as compared with 0.76 in pretreatment
years. The mean Expanded Disability Status Scale was lower after 2
years compared with pretreatment: 1.98 versus 2.3.
Recently, Hubbard et al107 treated 259 self-referred patients
who ‘reported an MS diagnosis from their local neurologist’ in an
open-label study. The patients paid for all diagnostic and
therapeutic procedures. After informed consent was signed,
MRV and selective venography were performed, followed by
balloon venoplasty. Apparently, 100% of patients who signed
informed consent were found to have stenoses, since all 259
patients were treated. Main outcome measures were MSIS-29
scores after 1 and 6 months. The percentage of questionnaires
completed after 1 and 6 months was 73.4 and 70.7, respectively.
On the MSIS-29 physical scale, a percentage of 67.9 were
improved, 25.8 were unchanged, and 6.3 were worse after 1
month; the percentages were 53.6, 35.5, and 10.9 after 6 months.
On the MSIS-29 psychological scale, a percentage of 53.0 were
improved, 42.2 were unchanged, and 4.9 were worse after 1
month; the percentages were 44.0, 51.1, and 4.5 after 6 months.
Although the authors claim ‘significant clinical improvement’, it
appears that the conclusion is not supported by their data. The
authors seem to be satisfied with an unverified diagnosis of MS.
After signing of informed consent, all 259 patients appeared to
have stenoses on selective venography and were found to need
treatment. Although similar figures were reported by the
cooperating groups of Zamboni and Zivadinov,8,108 others found
significantly lower percentages,28,29,92 while reliable data in
healthy control groups are lacking. There are no objective
outcome measures such as blinded neurologic examination or
MRI scans. The primary outcome measure is the subjective MSIS-
29 questionnaire. Placebo effects are very likely to occur in any
open-label setting. In this specific study, most of the patients were
self-referred and paid the costs for the treatment. This will likely
have biased the results toward reporting beneficial effects.
In June 2012, preliminary data were presented at a press
conference regarding a single blind, nonrandomized study of 30
MS patients who were treated by PTA and 10 untreated control
patients with 12-month follow-up. The study was funded by the
government of Newfoundland and Labrador (Canada). There was
no objective evidence of improvement as measured by neurologic
examination and MRI. The unblinded patients reported improve-
ments in physical and psychological well-being in the first 3
months after procedure. By now, there has been no peer reviewed
publication of these data (Newfoundland Labrador Multiple
Sclerosis Observational Study).
Two recent studies including 45 and 462 patients found no
support for a beneficial effect of PTA, although the retrospective
design does not permit us to draw any firm conclusions on the
basis of these two studies alone.109,110
In summary, all studies discussed in this section experience
methodological flaws. They are all of an open-label design and in
majority make use of subjective outcome measures. The New-
foundland study appears to have the best methodological design
so far, but has not been published. We have to conclude that there
is still no evidence at all to support the notion that balloon
venoplasty is effective in the treatment of MS. Placebo-controlled
trials are now underway. To avoid ongoing uncertainty in the
future, it will be extremely important that their design will meet
the same quality standards that are required nowadays of
potential drug treatments of MS.
SAFETY OF PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY
FOR MS/‘CHRONIC CEREBROSPINAL VENOUS INSUFFICIENCY’
Three studies looking at the safety of PTA in ‘CCSVI’ have been
reported so far. These data originate from clinics that offer PTA for
‘CCSVI’ to patients willing to pay for this treatment with unproven
efficacy.
The largest study is that of Petrov et al111 who report groin
hematomas (1%), cardiac arrhythmias (1.2%), vein rupture (0.4%),
vein dissection (3%), and thrombosis (1.6%) in a retrospective
cohort of 461 patients (stent placement in 16%) with MS.
Another group reported its experience with PTA (requiring stent
placement in B44%) of 331 patients with ‘CCSVI’.34 They found
groin hematomas (1.2%), cardiac arrhythmias (0.6%), stent throm-
bosis (1.2%), technical problems with stents and balloons (2.7%),
gastrointestinal bleeding (0.3%), and had to surgically remove one
angioplasty balloon (0.3%). It is not mentioned whether this was a
prospective or retrospectively examined cohort.
A third group reported a retrospectively observed cohort of 240
patients who had PTA (stent placement in 11%) for ‘CCSVI’, and
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had groin hematomas (0.8%), cardiac arrhythmias (1.2%), vein
thrombosis or dissection (10.1%), transient and persistent head-
aches (8.2% and 0.4%), transient neck pain (15.2%), and allergic
reactions to contrast agent (2.7%). More severe side effects were
thrombosis of the IJV (1.2%) and stress-induced cardiomyopathy
(‘takotsubo’) requiring intensive care admission.112
Over the past 2 years there have been several case reports
concerning patients who had serious side effects after PTA for
‘CCSVI’. These include IJV thrombosis requiring open thrombect-
omy;113 stent thrombosis and aneurysmal vein dilatation,
compression neuropathy of cranial nerves XI and XII, stent
migration to a renal vein, persistent extraperitoneal abdominal
hematoma, and stent thrombosis possibly extending from the left
IJV into the sigmoid sinus and transverse sinus.114
There are reports of one patient who died of (complications of)
PTA for ‘CCSVI’115 and media reports of three other MS patients
who allegedly died after PTA, but there are no medical
publications available (e.g., Details emerge about man who died
after MS therapy | CTV News).
In summary, it appears that most patients do not encounter
serious side effects of PTA for ‘CCSVI’. However, side effects do
occur, sometimes with serious consequences, and at least one
patient, and possibly more, died of the procedure.
Side effects, even lethal, might be acceptable in MS if there is
documented aggressive disease that does not react to first-line
treatments, such as interferon-beta and glatiramer acetate,116
and there is a second-line treatment with an established
and sufficiently large beneficial effect, as is the case with
natalizumab.117–119
In the case of PTA for ‘CCSVI’, there is no evidence for efficacy at
all, so that doctors treating MS patients with PTA accept a heavy
responsibility for any side effects that will occur, possibly with the
exception of patients treated in the setting of well-designed
clinical trials.
PATHOPHYSIOLOGIC CONSIDERATIONS
The pathophysiologic concept of CCVSI in MS is based on the
assumption that impaired venous outflow with reflux and venous
congestion, which leads to perivascular diapedesis of blood cells
inducing perivascular inflammation and pathologic iron accumu-
lation associated with an acceleration of neurodegenerative
pathology.120 At first glance, this theory might be logical since
perivascular (perivenous) inflammation and neurodegeneration
including increased iron deposition in the basal ganglia are
important features of MS pathology. However, this proposed
pathophysiologic concept of ‘CCSVI’ in MS completely disregards
the complexity and heterogeneity of MS pathophysiology as well
as epidemiologic and environmental features.121–123
It is completely unclear how to link ‘CCSVI’ to several hallmarks
of MS pathophysiology such as a B-cell and T-cell mediated
autoimmune response and subsequent neuronal and axonal
damage.124–128 In addition, ‘CCSVI’ cannot explain the MS
lesion heterogeneity of white and gray matter that show
different histopathologic characteristics.129,130 ‘CCSVI’ mainly
refers to perivascular inflammation but lacks any explanation of
diffuse demyelination in the white and gray matter (white and
gray matter pathology). Increased and accelerated iron deposition
is an unspecific neurodegenerative marker not exclusively being
present in MS but also in many other neurodegenerative disorders
such as Alzheimer’s dementia, and probably also in the normal
aging brain.131 In addition, based on the CCSVI theory, it could be
expected that increased iron deposition can be detected also
diffusely in the white matter which has not been described so far.
Venous outflow impairment has not been associated with
primary neurodegenerative diseases so far. If ‘CCSVI’ is associated
with MS pathology, then we have to consider patients with real
pathologic venous outflow. Chronic venous outflow changes like
those in postoperative situation in head and neck cancer patients
(neck dissection) or in patients with sinus-venous thrombosis or
other diseases with an increased central venous pressure have not
been linked to MS pathology so far.20,132,133 In other words, higher
incidence of MS in these patient groups has not been reported so
far. In addition, venous outflow impairment of the central nervous
system should lead to an increased intracranial pressure. However,
an increased intracranial pressure has not been reported to be
frequent in MS patients. If the ‘CCSVI’ theory was plausible, then
one would also expect impairment of the drainage in the retinal
and ophthalmic venous systems that drain into the IJVs. However,
this is obviously not the case,134 and while retinal nerve fiber layer
atrophy as detected by optical coherence tomography is a well-
acknowledged feature of MS,135 no evidence for impaired venous
outflow from retinal veins has been reported in thousands of MS
patients who have been investigated by this technique despite
the excellent visibility of the retinal vessels with modern spectral
domain optical coherence tomography technology.136,137
Besides this implausibility of the ‘CCSVI’ theory in terms of
pathophysiology, also other important factors that are strongly
associated with MS call the ‘CCSVI’ concept into question. Genetic
susceptibility factors of MS like the major histocompatibility
complex and non major histocompatibility complex loci have
not been linked to venous pathology.25,138 Local differences
in MS prevalence in terms of geographic distribution should
consequently also be associated with different prevalence of
venous outflow impairment. However, this has not been reported
so far. Multiple sclerosis is more frequent in younger patients and
in women.139,140 Arterial and venous vessel pathologies are more
likely to occur in older patients and in male patients. In addition,
Vitamin D deficiency and Epstein-Barr virus infections, important
environmental factors associated with MS, are not likely to be
associated with venous outflow pathology.141–144
In conclusion, there is no single convincing pathophysiologic or
epidemiologic argument supporting the concept that chronic
venous outflow changes in terms of ‘CCSVI’ are associated with MS
pathology or higher MS incidence and prevalence.
CONCLUSION
In line with other recent reviews on this topic,79,145 this review
article conclusively stresses that the serious methodological limits
and misinterpretation of findings should be reason enough to halt
the completely unsubstantiated ‘CCSVI’-based interventional
therapy for MS patients. Calling for controlled studies misses the
point, because this suggests that the interventional therapies
should be continued (possibly over many years) until definitive
results are available. The interventions are expensive, thousands of
Euros, causing a significant financial burden but more important
impose a concrete health risk onto our MS patients. Only a
complete halt to the therapy seems sensible.
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